ASCO 2025 Press Releases

Viewing 1-7 of 7 articles

Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC

Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Bicycle Therapeutics to Present Data in Locally Advanced or Metastatic Urothelial Cancer at ASCO 2025

ASCO 2025: Phase III ARANOTE Post-Hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (Darolutamide) plus ADT

New Novartis Data at ASCO and EHA Showcase Momentum of Pioneering Portfolio with Promising Pipeline

Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025